Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial by 정인경 et al.
METHODOLOGY Open Access
Upfront radical surgery with total
mesorectal excision followed by adjuvant
FOLFOX chemotherapy for locally advanced
rectal cancer (TME-FOLFOX): an open-label,
multicenter, phase II randomized controlled
trial
Jii Bum Lee1†, Han Sang Kim1,2†, Inkyung Jung3, Sang Joon Shin1, Seung Hoon Beom1, Jee Suk Chang4,
Woong Sub Koom4, Tae Il Kim5, Hyuk Hur6, Byung Soh Min6, Nam Kyu Kim6, Sohee Park7, Seung-Yong Jeong8,
Jeong-Heum Baek9, Seon Hahn Kim10, Joon Seok Lim11, Kang Young Lee6† and Joong Bae Ahn1,2*†
Abstract
Background: Preoperative chemoradiotherapy (PCRT) followed by surgery and adjuvant chemotherapy is the
current standard treatment for stage II/III rectal cancer. However, radiotherapy in the pelvic area is commonly
associated with complications such as anastomotic leakage, sexual dysfunction, and fecal incontinence. Recently,
the MERCURY study showed that preoperative high-resolution magnetic resonance imaging (MRI) helped to
selectively avoid PCRT. It remains unclear whether PCRT is necessary in patients who can achieve a negative
circumferential resection margin (CRM) with surgery alone and in patients with cT1–2N1 or cT3N0 without CRM
involvement and lateral lymph node metastasis. This study aims to evaluate the efficacy of upfront radical surgery
with total mesorectal excision (TME) followed by adjuvant chemotherapy with folinic acid (or leucovorin),
fluorouracil, and oxaliplatin (FOLFOX) versus the current standard treatment in patients with surgically resectable,
locally advanced rectal cancer.
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Methods: This study, named TME-FOLFOX, is a prospective, open-label, multicenter, phase II randomized trial.
Patients with locally advanced rectal cancer will be randomized to receive PCRT followed by TME and adjuvant
chemotherapy (arm A) or upfront radical surgery with TME followed by adjuvant FOLFOX chemotherapy (arm B).
Clinical stage II/III rectal cancer without CRM involvement and lateral lymph node metastasis will be defined using
preoperative MRI. The primary endpoint is 3-year disease-free survival (DFS). Secondary endpoints include 5-year
DFS, local recurrence rate, systemic recurrence rate, cost-effectiveness, and overall survival. We hypothesized that
our experimental group (arm B) will have a 3-year DFS of 75% and a non-inferiority margin of 15%.
Discussion: Identifying whether patients require PCRT is one of the critical issues in locally advanced rectal cancer.
This study aims to elucidate whether PCRT may not be required for all patients with stage II/III rectal cancer,
especially for the MRI-based intermediate-risk group (with cT1–2N1 or cT3N0) without CRM involvement and lateral
lymph node metastasis. If the findings indicate that our proposed treatment, which omits PCRT, is non-inferior to
the standard treatment, then patients may avoid unnecessary radiation-related toxicity, have a shorter treatment
duration, and save on medical costs.
Trial registration: ClinicalTrials.gov, NCT02167321. Registered on 19 June 2014.
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Introduction
Colorectal cancer (CRC) remains the third most com-
mon malignancy and the second leading cause of
cancer-related death worldwide [1]. In South Korea, the
increasing prevalence of the westernized diet is corre-
lated with a rising incidence of CRC. In 23,271 Korean
patients who were diagnosed with CRC in 2018, about
50% of CRC cases were categorized as rectal cancer [2].
Currently, the standard treatment for stage II/III rectal
cancer is preoperative chemoradiotherapy (PCRT)
followed by surgery and adjuvant chemotherapy [3]. In
the past, local relapse after surgery had been the main
issue with treatment [4]. However, since the introduc-
tion of total mesorectal excision (TME), the incidence of
local recurrence has decreased to < 10% [5–7].
The addition of PCRT also led to a decrease in tumor
size and local relapse rate [8, 9] and an increase in
disease-free survival (DFS); however, it did not have an
impact on overall survival (OS) [10]. Thus, the need to
control distant metastasis poses as a challenging issue.
Although radiotherapy is an effective means of local
control, complications such as anastomotic leakage, sex-
ual dysfunction, and fecal incontinence are very com-
mon in patients receiving radiotherapy in the pelvic area
[11–13]. In addition, PCRT usually takes up to 3 months
[14], thereby prolonging the treatment period and in-
creasing the financial burden on patients.
Adjuvant chemotherapy is vital to controlling the
systemic recurrence rate, especially in locally ad-
vanced rectal cancer. Adjuvant chemotherapy with
folinic acid (or leucovorin), 5-fluorouracil (5-FU), and
oxaliplatin (FOLFOX) is associated with a 3-year DFS
superior to that of 5-FU monotherapy for stage III
rectal cancer [15, 16]. The pivotal ADORE trial and
the German CAO/ARO/AIO-04 study further
supported the efficacy of FOLFOX in the adjuvant
setting [17, 18].
Despite the multimodality of the approach to treating
locally advanced rectal cancer, some patients are not eli-
gible for PCRT. In the MERCURY study, preoperative
high-resolution magnetic resonance imaging (MRI)
helped to selectively avoid PCRT [19]. The QuickSilver
study also showed that selecting patients with a “good
prognosis” using MRI resulted in a low rate of positive
circumferential resection margin (CRM) in patients who
received upfront surgery [20]. Therefore, the identifica-
tion of patients who are not eligible for PCRT is one of
the critical issues in locally advanced rectal cancer.
Whether PCRT is a prerequisite for patients who can
achieve a negative CRM with surgery alone warrants fur-
ther study [21]. If surgery alone can provide local con-
trol, then patients can receive adjuvant treatment earlier,
preventing systemic relapse.
In this study, we aim to evaluate the efficacy of upfront
radical surgery with TME followed by adjuvant FOLFOX
chemotherapy in patients with surgically resectable, lo-
cally advanced rectal cancer. We hypothesized that the
3-year DFS of patients receiving our proposed treatment
will be non-inferior to that of patients receiving the
current standard treatment for stage II/III rectal cancer.
Patients and methods
Study design
This study is an open-label, multicenter, phase II ran-
domized controlled trial and will include patients from
five tertiary hospitals in South Korea. Patients will be
randomly allocated in a 1:1 ratio using random per-
muted blocks. Factors such as institution and clinical
lymph node stage (positive or negative) will be consid-
ered when allocating the subjects into one of the
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following groups: standard treatment group (arm A) or ex-
perimental treatment group (arm B) (Fig. 1). Initially, arm
A will receive fluoropyrimidine-based or capecitabine-
based PCRT (45 ± 5.4 Gy/28 fractions/5.5 weeks, concur-
rent) followed by TME. Patients will be further stratified
into low-risk or high-risk groups for recurrence based on
their clinicopathological findings (Fig. 2).
High-risk features include T4 lesion, poor histologic
grade, peritumoral lymphovascular involvement, peri-
neural invasions, bowel obstruction at initial presenta-
tion, T3 lesion with localized or impending perforation,
and an indeterminate or positive margin [22]. Low-risk
patients (with ypT0–2N0) will receive adjuvant chemo-
therapy with fluoropyrimidine and leucovorin or with
capecitabine. High-risk patients (with ypT3–4N0 or ypTa-
nyN1–2) will be treated with 8 cycles of adjuvant FOL-
FOX chemotherapy. Arm B will undergo TME followed
by 12 cycles of adjuvant FOLFOX chemotherapy.
The regimens to be used in this study are as follows.
During radiotherapy, patients may be given 5-FU or capeci-
tabine. A fluoropyrimidine-based regimen of 5-FU 400mg/
m2 and leucovorin 20mg/m2 will be given intravenously on
days 1–3 and days 29–31. Capecitabine 825mg/m2 will be
administered orally twice a day during radiotherapy.
In the adjuvant setting, low-risk patients will receive
either the leucovorin regimen or capecitabine. The post-
operative leucovorin regimen will consist of 5-FU 400
mg/m2 and leucovorin 20mg/m2 given as an intravenous
bolus on days 1–5 every cycle (28 days). Capecitabine
1250 mg/m2 will be administered orally twice a day on
days 1–14 every cycle (21 days). The high-risk group of
arm A and arm B will be treated with FOLFOX for 8
and 12 cycles, respectively. The regimen consists of: 5-
FU 400mg/m2 administered as an intravenous bolus on
day 1, followed by 1200 mg/m2 given intravenously over
24 h on days 1–2; oxaliplatin 85 mg/m2 administered
intravenously; and leucovorin 200 mg/m2 administered
intravenously on day 1.
Patients are to visit the clinic every 3 months for 3
years after surgery and 6months thereafter. Follow-up
appointments will include physical examination,
complete blood count, routine chemistry including liver
and kidney function tests, and serum carcinoembryonic
antigen test. Chest radiography and abdominal and pel-
vic computed tomography will be performed every 6
months for 5 years. A routine colonoscopy will also be
performed 1, 3, and 5 years after surgery. Every year for
3 years, we will ask patients to answer surveys to evalu-
ate their quality of life.
Study population
Patient selection is based on the following inclusion and
exclusion criteria.
Inclusion criteria
1. Histologically confirmed adenocarcinoma of the
rectum below 10 cm from the anal verge
2. Locally advanced rectal cancer (T3N0 or T1–
3Npositive)
locally advanced rectal cancer
enrollment and patient stratification
informed patient consent
Arm A: standard treatment 
Neoadjuvant CRT with  
fluoropyrimidine + TME + 
adjuvant chemotherapy 
(fluoropyrimidine or mFOLFOX)
Arm B: experimental treatment
Upfront TME + adjuvant 
chemotherapy (mFOLFOX)
Follow up and data analysis
Primary end-point: 3-year DFS





Fig. 1 Flow diagram of the trial. DFS disease-free survival, OS overall survival, TME total mesorectal excision, CRT chemoradiotherapy, mFOLFOX
modified FOLFOX, folinic acid (or leucovorin), 5-fluorouracil, and oxaliplatin
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3. No evidence of para-aortic, common, or external
iliac lymph node metastasis
4. Distance of > 2 mm between the primary tumor and
mesorectal fascia on pelvic MRI
5. Male or female aged 19–80 years
6. Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2
7. Preoperative American Society of Anesthesiologists
(ASA) physical status class of I–III
8. No prior systemic chemotherapy including
chemotherapy, immunotherapy, or radiotherapy for
rectal cancer
9. No previous history of radiotherapy within the
pelvic cavity
10. Adequate organ function based on the following
parameters:
(a) Absolute neutrophil count ≥ 1.5 × 103/L
(b) Platelet count ≥ 100 × 109/L
(c) Adequate renal function: creatinine ≤ 1.5 times
the upper limit of normal (ULN) or glomerular
filtration rate of creatinine clearance (calculated
using the Cockcroft–Gault formula) > 50ml/min
(d) Adequate hepatic function: alanine
aminotransferase-to-aspartate aminotransferase
ratio ≤ 2.5 × ULN or total bilirubin ≤ 1.5 × ULN
11. Patients who are willing and able to comply with
the protocol during the study
12. Patients with written informed consent
Exclusion criteria
1. Rectal malignancy other than adenocarcinoma or
adenocarcinoma that developed from inflammatory
bowel disease
2. Suspicious distant metastasis
3. Grade ≥ 1 peripheral neuropathy according to the
National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE)
4. Patients receiving concomitant treatment with
drugs interacting with 5-FU or oxaliplatin (e.g., flu-
cytosine, phenytoin, warfarin)
5. Uncontrolled and significant cardiovascular disease
with heart failure of class III or IV according to the
New York Heart Association (NYHA) classification,
myocardial infection, or uncontrolled angina
pectoris within the past 6 months
6. Prior hypersensitivity reaction to fluoropyrimidine or
known dihydropyrimidine dehydrogenase deficiency
7. Hereditary disease such as galactose intolerance,
Lapp lactase deficiency, or glucose–galactose
malabsorption
8. Known hypersensitivity to platinum-based drugs,
leucovorin, or capecitabine
9. Treatment with bevacizumab, cetuximab,
oxaliplatin, or irinotecan





2) cT3, N0 or cT1-3, N+






2) lymph node status
(positive vs. negative) 
3-6 weeks 6 months
Fluoropyrimidine based adjuvant chemotherapy 
FL (4 cycles) or capecitabine (5 cycles)
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Adjuvant mFOLFOX-6 (8 cycles)
5-5.5 weeks 
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Fluoropyrimidine based adjuvant chemotherapy 
Fig. 2 Study treatment. PCRT preoperative chemoradiotherapy, TME total mesorectal excision, AV anal verge, MRF mesorectal fascia, FL 5-
fluorouracil and leucovorin, mFOLFOX: modified FOLFOX, folinic acid (or leucovorin), 5-fluorouracil, and oxaliplatin
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11. Patients who received organ transplantation
requiring immunosuppressive treatment
12. Uncontrolled epilepsy or psychiatric disease
13. A pregnant or lactating female patient
Safety and quality
Adverse events will be evaluated according to CTCAE
version 4.0. Other measures also include total score for
function of urination (International Prostate Symptom
Score (IPSS)) and defecation score (Wexner’s score).
Quality of life will be assessed using the Korean version
of the European Organization for Research and Treat-
ment of Cancer Quality-of-Life Questionnaire (EORTC
QLQ-C30).
Results
The primary endpoint is 3-year DFS of patients receiving
our proposed treatment versus the standard treatment
for surgically resectable, locally advanced rectal cancer.
DFS is defined as the time from randomization to dis-
ease progression or death from any cause. Secondary
endpoints include 5-year DFS, local recurrence rate, sys-
temic recurrence rate, cost-effectiveness, and OS. OS is
defined as the time from initial diagnosis to death from
any cause.
Statistical analysis
The primary purpose of this study is to test the non-
inferiority of TME followed by 12 cycles of adjuvant
FOLFOX chemotherapy to the current standard treat-
ment of PCRT followed by TME and adjuvant chemo-
therapy. This study is based on the results of the
COREAN trial, which showed a 3-year DFS of 72.5%
and 79.2% for open and laparoscopic surgery of mid and
low rectal cancer, respectively [23]. We estimated that
experimental group (arm B) will have a 3-year DFS of
75% and a non-inferiority margin of 15% [24]. To prove
non-inferiority [25], we set the upper limit of the one-
sided 85% confidence interval of the difference as 15%.
With a statistical power of 70%, a one-sided α error of
15%, and a 10% dropout rate, we estimated a total of 90
patients for this study, with 45 patients for each arm.
Our analysis will be based on an intention-to-treat
population and a per-protocol population. Continuous
and categorical variables will be analyzed using the
Mann–Whitney test and Fisher’s exact test, respectively.
Spearman’s correlation test will be used for correlation
analyses. The Kaplan–Meier method will be used to esti-
mate DFS, OS, and local and distant recurrence, and the
log-rank (Mantel–Cox) tests to compare survival distri-
bution. The significance level is set at p < 0.05, and all
statistical tests will be two-sided. There will be no in-
terim analysis.
Translational analyses
Using next-generation sequencing technology, we will
perform biomarker analysis and gene expression profil-
ing of surgically resected rectal specimens. The results
may provide insight into biomarkers that can predict re-
sponses, outcomes, and recurrence in patients with lo-
cally advanced rectal cancer.
Data collection, management, and monitoring
Patient data will be effectively managed using the eVelos
system, a web-based clinical trial management system
(http://kcpc.ncc.re.kr; Velos Inc., Fremont, CA, USA).
We estimated the patient accrual and study duration to
take 4 and 5 years, respectively.
Discussion
Although the multimodality of approach for treating lo-
cally advanced rectal cancer has lowered the local recur-
rence rate and improved DFS, approximately one-third
of patients still experience systemic recurrence [10].
PCRT may help to downsize tumors and provide local
control [23], but its role is questionable if patients with a
negative CRM may be eligible for TME alone using
high-resolution MRI [19]. Our study aims at proving the
non-inferiority of TME followed by 12 cycles of adjuvant
FOLFOX chemotherapy to the standard treatment of
PCRT followed by TME and adjuvant chemotherapy. If
our findings reveal that our proposed treatment method,
which omits PCRT, is non-inferior to the standard treat-
ment, then patients may avoid unnecessary radiation-
related toxicity, have shorter treatment duration, and
save on medical costs. The results of our translational
research also provide important insights into biomarkers
associated with radiotherapy.
Selective approaches to radiotherapy for clinical stage
II/III rectal cancer are currently one of the unmet needs
of patients in this field. Our study will be comparable to
the MERCURY, OCUM, or QuickSilver study, all of
which used high-resolution MRI to select patients with a
good prognosis, defined as a negative CRM [19, 20, 26].
These studies had CRM rates of 2–5% and 5-year local
recurrences rates of 2.0–3.3% in patients without PCRT,
suggesting that precise clinical staging based on high-
resolution MRI can help avoid unnecessary PCRT in pa-
tients with a good prognosis. Considering the impact of
PCRT on local control, the rate of CRM involvement
and the rate of completing a TME procedure will be
critical factors in this study.
Our study was registered at ClinicalTrials.gov
(NCT02167321) on June 19, 2014. Patient accrual began
in December 2014. Patients will be followed up until
June 2024.
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